Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis

INTRODUCTION: Invasive aspergillosis (IA) is associated with a significant clinical and economic burden. The phase III SECURE trial demonstrated non-inferiority in clinical efficacy between isavuconazole and voriconazole. No studies have evaluated the cost-effectiveness of isavuconazole compared to...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrington, Rachel, Lee, Edward, Yang, Hongbo, Wei, Jin, Messali, Andrew, Azie, Nkechi, Wu, Eric Q., Spalding, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216061/
https://www.ncbi.nlm.nih.gov/pubmed/27913989
http://dx.doi.org/10.1007/s12325-016-0443-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216061/
https://www.ncbi.nlm.nih.gov/pubmed/27913989
http://dx.doi.org/10.1007/s12325-016-0443-1

Ejemplares similares